Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer pivots to 'externalization" of rare disease programs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 06, 2023 1:52pm

147 Views

Post# 35207417

RE:Pfizer pivots to 'externalization" of rare disease programs

“This approach will allow us to focus on programs where our innovation and investments are differentiated and where we are best positioned to generate high-impact medicines and vaccines"

- sounds like Pfizer is seeking to differentiate their investment into a company like ONCY with a high impact medicine in the treatment of multiple cancers.

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army